| MON, 26 November 2018 |
|
|
| |
|
|
| 17:30 - 19:00 |
Welcome reception in the Dan Hotel |
|
| |
|
|
| TUE, 27 November 2018 |
|
|
| |
|
|
| 08:15 - 09:00 |
Registration |
|
| 09:00 - 09:05 |
Opening |
|
| |
|
|
| |
Experimental Uveitis Models in 2018 |
|
| |
|
|
| 09:05 - 09:25 |
Regulation of Th17 response by IL-17:
implications for autoimmunity |
Rachel Caspi |
| 09:25 - 09:45 |
Lessons from experimental rat models for
chronic and relapsing autoimmune uveitis |
Gerhild Wildner |
| 09:45 - 10:05 |
Of mice and men and women |
James Rosenbaum |
| 10:05 - 10:20 |
Discussion |
|
| |
|
|
| |
The Role of Microbiome in Uveitis |
|
| |
|
|
| 10:45 - 11:00 |
Welcome to the World of Microbiota |
Nida Sen |
| 11:00 - 11:18 |
Microbiome and the Eye-the good and the bad |
Rachel Caspi |
| 11:18 - 11:38 |
Microbiome and Tuberculosis |
Florian Hoelzl |
| 11:38 - 11:56 |
Microbiome and HLA-B27 |
James Rosenbaum |
| 11:56 - 12:16 |
Virome and the Eye |
Jolanda D.F de Groot-Mijnes |
| 12:16 - 12:30 |
Discussion |
|
| |
|
|
| |
Multimodal Imaging (MMI) for Inflammatory Outer Retinopathies |
|
| |
|
|
| 13:30 - 13:42 |
What have we learned from MMI about
inflammatory outer retinopathies |
Michal Kramer |
| 13:42 - 13:54 |
Insights to outer retinopathies from OCTA and Adaptive Optics |
Padmamalini Mahendradas |
| 13:54 - 14:04 |
Clues for inflammation by MMI of rarest entities |
Orly Gal-Or |
| 14:04 - 14:16 |
Clinical application of Artificial Intelligence and Machine Learning |
Noam Bresiz |
| 14:16 - 14:26 |
The way to use Artificial Intelligence and
machine learning in Uveitis Diagnosis |
Antoine Brezin |
| 14:26 - 14:36 |
How MMI changes our management of
inflammatory outer retinopathies |
Padmamalini Mahendradas |
| 14:36 - 14:45 |
Discussion |
|
| |
|
|
| 15:15 - 16:15 |
Controversies |
|
| |
|
|
| |
1. Systemic vs intraocular steroid therapy
for acute toxoplasmic retinochoroiditis |
pro systemic: Emmett Cunningham
pro intraocular: Rubens Belfort |
| |
2. Biologics vs immunosuppressives as
first line treatment for JIA-induced uveitis |
pro Biologics: Athimalaipet V. Ramanan
pro Immunosuppressives: Debra Goldstein |
| |
3. Treatment of Behcet´s Disease: anti-TNF vs interferon alpha |
pro: anti-TNF-alpha: Shiri Shulman
pro: interferon alpha: Manfred Zierhut |
| |
|
|
| |
Progression Markers |
|
| |
|
|
| 16:15 - 16:25 |
Progression markers of Vogt Koyanagi Haradas Disease |
Nobuyoshi Kitaichi |
| 16:25 - 16:35 |
Biomarkers for increased risk of developing uveitis in JIA |
Joke de Boer |
| 16:35 - 16:45 |
Laser flare photometry can predict a recurrence in Behçet-uveitis |
Nilüfer Yalcindag |
| 16:45 - 17:00 |
Discussion |
|
| |
|
|
| WED, 28 November 2018 |
|
|
| |
|
|
| 08:30 - 09:00 |
Registration (new participants) |
|
| |
|
|
| |
Tuberculosis - From Infection to Inflammation |
|
| |
|
|
| 09:00 - 09:12 |
Immunology of general TB infection |
Florian Hoelzl |
| 09:12 - 09:24 |
Immunology of ocular TB infection |
Soumyava Basu |
| 09:24 - 09:36 |
Update of the the COTS-studies |
Reema Bansal |
| 09:36 - 09:48 |
Clinical spectrum of “inflammatory” TB |
Vasconcellos-Santos Daniel |
| 09:48 - 10:00 |
Quantiferon testing in endemic vs. non-endemic areas |
Soon Phaik Chee |
| 10:00 - 10:15 |
Discussion |
|
| |
|
|
| |
Preparing for Intraocular Surgery in Uveitis Patients |
|
| |
|
|
| 10:45 - 11:00 |
General principles of medical preparation for
intraocular surgery in uveitis |
|
| 11:00 - 11:15 |
Intra- and perioperative care during cataract surgery |
|
| 11:15 - 11:30 |
Preparing for glaucoma drainage and vitrectomy in uveitis |
|
| 11:30 - 12:30 |
Round Table |
Moderator: Nicholas Jones Cristina Muccioli,
Nisha Acharya, Matthias Becker |
| |
|
|
| |
Uveitis Related Macular Edema |
|
| |
|
|
| 13:30 -13:50 |
Differences between Uveitis macular edema and other etiologies |
Francine Behar Cohen |
| 13:50 - 14:00 |
Role of Cytokines in uveitis related CME |
Marina Mesquida |
| 14:00 - 14:15 |
Macular edema-what have the MUST trials taught us |
Sue Lightman |
| 14:15 - 14:30 |
Options for treatment of uveitis related CME |
Marina Mesquida |
| 14:30 - 14:40 |
Biologics and uveitic CME |
Oren Tomkins |
| 14:40 - 15:00 |
Discussion |
|
| |
|
|
| |
Future Protocols for Uveitis Trials |
|
| |
|
|
| 15:30 - 15:35 |
Introduction |
Philip Murray |
| 15:35 - 15:50 |
The Problem of outcome measurements in uveitis trials |
Nisha Acharya |
| 15:50 - 06:03 |
Clinical trials in uveitis-The Industry Perspective |
Ron Neuman |
| 16:03 - 16:16 |
Clinical trials in uveitis-The Reading Center Perspective |
Marion Munk |
| 16:16 - 16:29 |
Why previous uveitis trials often failed |
James Rosenbaum |
| 16:29 - 17:00 |
Round Table: What would be your ideal uveitis trial |
Moderator: Philip Murray |
| |
|
|
| THU, 29. November 2018 |
|
|
| |
|
|
| 08:30 - 09:00 |
Registration (new participants) |
|
| |
|
|
| |
Biologic Agents for Uveitis |
|
| |
|
|
| 09:00 - 09:12 |
Definition of “Failure” under biologic drugs |
Debra Goldstein |
| 09:12 - 09:24 |
Biologics inducing uveitis |
Manfred Zierhut |
| 09:24 - 09:36 |
Side effects of biologics and biosimilars |
Martin van Hagen |
| 09:36 - 09:48 |
Off label biologics as the next step |
Eric Suhler |
| 09:48 - 10:15 |
Discussion |
|
| |
|
|
| 10:45 - 12:00 |
Case Reports |
Chairs: Careen Lowder, Massimo Accorinti,
Zohar Habot-Wilner |
| |
|
Mystery Cases - Israeli Uveitis Group |
| |
|
|
| 12:00 - 12:30 |
Presentation of the best 5 Posters |
|
| |
|
|
| |
Uveitis in Immune Incompetent Patients |
|
| |
|
|
| 13:30 - 13:42 |
AIDS associated Uveitis in 2018 |
Jyotirmay Biswas |
| 13:42 - 13:54 |
Role of CMV in immune incompetence |
Alejandra dela Torre |
| 13:54 - 14:06 |
Post-Transplantation-Lymphoproliferative disorders |
Manfred Zierhut |
| 14:06 - 14:18 |
Immune mediated ocular toxicity following the use
of Immune Checkpoint Inhibitors for malignancy |
Nida Sen |
| 14:18 - 14:30 |
Carcinoma-associated Uveitis |
Radgonde Amer |
413